$-1.18 EPS Expected for Theravance Biopharma, Inc. (TBPH)

October 13, 2018 - By Peter Erickson

Theravance Biopharma, Inc. (NASDAQ:TBPH) LogoInvestors sentiment decreased to 1.09 in 2018 Q2. Its down 0.26, from 1.35 in 2018Q1. It is negative, as 10 investors sold Theravance Biopharma, Inc. shares while 25 reduced holdings. 12 funds opened positions while 26 raised stakes. 35.37 million shares or 0.68% less from 35.61 million shares in 2018Q1 were reported.
Schwab Charles Invest stated it has 226,268 shares or 0% of all its holdings. 222,525 were reported by Goldman Sachs Grp. Envestnet Asset Management Inc reported 677 shares. Signaturefd Limited Company holds 200 shares or 0% of its portfolio. Jacobs Levy Equity Mngmt stated it has 0.07% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Price T Rowe Assocs Md stated it has 0.01% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Alliancebernstein Lp invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Blackrock reported 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Credit Suisse Ag holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 49,184 shares. Rhumbline Advisers has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Baupost Gp Limited Liability Com Ma has invested 1.85% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Piedmont Invest Advsrs Limited Liability reported 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Invesco Ltd accumulated 22,204 shares. Peak6 Invests L P invested 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Bnp Paribas Arbitrage invested in 2,197 shares.

Since May 18, 2018, it had 1 buying transaction, and 5 insider sales for $2.11 million activity. Another trade for 6,393 shares valued at $182,201 was made by WORBOYS PHILIP D on Wednesday, September 12. $242,877 worth of Theravance Biopharma, Inc. (NASDAQ:TBPH) shares were sold by GALA RENEE D. On Monday, August 27 the insider Shafer Bradford J sold $197,282.

Analysts expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to report $-1.18 EPS on November, 6.They anticipate $0.09 EPS change or 7.09 % from last quarter’s $-1.27 EPS. After having $-0.76 EPS previously, Theravance Biopharma, Inc.’s analysts see 55.26 % EPS growth. The stock increased 0.34% or $0.1 during the last trading session, reaching $29.94. About 125,502 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 11.71% since October 14, 2017 and is downtrending. It has underperformed by 27.33% the S&P500.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.65 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More notable recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on October 12, 2018, also Streetinsider.com with their article: “Theravance Biopharma (TBPH), Mylan (MYL) Report Positive New Data from Multiple Studies of YUPELRI at CHEST” published on October 11, 2018, Seekingalpha.com published: “Your Daily Scoop: Unum’s Positive Data, Theravance’s Treatment Benefit, Collectar’s New Designation” on September 21, 2018. More interesting news about Theravance Biopharma, Inc. (NASDAQ:TBPH) were released by: Seekingalpha.com and their article: “An Updated Investment View On Theravance Biopharma” published on October 04, 2018 as well as Bizjournals.com‘s news article titled: “Health Care Digest: Upsized record IPO, e-cigarette questions, a CEO Dance and more” with publication date: October 08, 2018.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>